Characteristic | Crude HR (95% CI) | P-value* (bivariatea) | Adjusted HR (95% CI) | P-value* (multivariablea) |
---|---|---|---|---|
Primary tumor location | ||||
Right vs. Left | 2.29 (1.46–3.62) | <0.001 | 1.84 (1.10–3.09) | 0.021 |
Age | ||||
>60 years vs. ≤ 60 | 1.06 (0.76–1.47) | 0.750 | 1.07 (0.75–1.51) | 0.720 |
Gender | ||||
Female vs. Male | 0.92(0.65–1.30) | 0.623 | 0.97 (0.66–1.40) | 0.852 |
Stage at presentation | ||||
Stage IV vs. Stage I-III | 1.12 (0.77–1.63) | 0.554 | ||
Histologic grade | ||||
P/D or SRC vs. W/D or M/D | 4.35 (2.21–8.57) | <0.001 | 3.08 (1.49–6.34) | 0.002 |
Presence of liver metastasis | ||||
Yes vs. No | 1.29 (0.91–1.82) | 0.156 | ||
Presence of lung metastasis | ||||
Yes vs. No | 0.84 (0.61–1.15) | 0.279 | ||
Presence of peritoneal metastasis | ||||
Yes vs. No | 2.91 (1.79–4.75) | <0.001 | 2.05 (1.17–3.60) | 0.013 |
Number of metastasized organs | ||||
≥ 2 vs. 1 | 1.10 (0.80–1.52) | 0.540 | ||
BRAF | ||||
Mutant vs. Wild-type | 3.24 (1.94–5.43) | <0.001 | 2.84 (1.60–5.03) | <0.001 |
PIK3CA | ||||
Mutant vs. Wild-type | 1.97 (0.80–4.84) | 0.138 |